Literature DB >> 16294220

Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.

Girish S Kirimanjeswara1, Luis M Agosto, Mary J Kennett, Ottar N Bjornstad, Eric T Harvill.   

Abstract

Whooping cough is considered a childhood disease, although there is growing evidence that children are infected by adult carriers. Additionally, increasing numbers of vaccinated adults are being diagnosed with Bordetella pertussis disease. Thus it is critical to understand how B. pertussis remains endemic even in highly vaccinated or immune populations. Here we used the mouse model to examine the nature of sterilizing immunity to B. pertussis. Antibodies were necessary to control infection but did not rapidly clear B. pertussis from the lungs. However, antibodies affected B. pertussis after a delay of at least a week by a mechanism that involved neutrophils and Fc receptors, suggesting that neutrophils phagocytose and clear antibody-opsonized bacteria via Fc receptors. B. pertussis blocked migration of neutrophils and inhibited their recruitment to the lungs during the first week of infection by a pertussis toxin-dependent (PTx-dependent) mechanism; a PTx mutant of B. pertussis induced rapid neutrophil recruitment and was rapidly cleared from the lungs by adoptively transferred antibodies. Depletion of neutrophils abrogated the defects of the PTx mutant. Together these results indicate that PTx inhibits neutrophil recruitment, which consequently allows B. pertussis to avoid rapid antibody-mediated clearance and therefore successfully infect immune hosts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294220      PMCID: PMC1283938          DOI: 10.1172/JCI24609

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  66 in total

1.  Stereotyped and specific gene expression programs in human innate immune responses to bacteria.

Authors:  Jennifer C Boldrick; Ash A Alizadeh; Maximilian Diehn; Sandrine Dudoit; Chih Long Liu; Christopher E Belcher; David Botstein; Louis M Staudt; Patrick O Brown; David A Relman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.

Authors:  Julian Parkhill; Mohammed Sebaihia; Andrew Preston; Lee D Murphy; Nicholas Thomson; David E Harris; Matthew T G Holden; Carol M Churcher; Stephen D Bentley; Karen L Mungall; Ana M Cerdeño-Tárraga; Louise Temple; Keith James; Barbara Harris; Michael A Quail; Mark Achtman; Rebecca Atkin; Steven Baker; David Basham; Nathalie Bason; Inna Cherevach; Tracey Chillingworth; Matthew Collins; Anne Cronin; Paul Davis; Jonathan Doggett; Theresa Feltwell; Arlette Goble; Nancy Hamlin; Heidi Hauser; Simon Holroyd; Kay Jagels; Sampsa Leather; Sharon Moule; Halina Norberczak; Susan O'Neil; Doug Ormond; Claire Price; Ester Rabbinowitsch; Simon Rutter; Mandy Sanders; David Saunders; Katherine Seeger; Sarah Sharp; Mark Simmonds; Jason Skelton; Robert Squares; Steven Squares; Kim Stevens; Louise Unwin; Sally Whitehead; Bart G Barrell; Duncan J Maskell
Journal:  Nat Genet       Date:  2003-08-10       Impact factor: 38.330

3.  Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin.

Authors:  G J Spangrude; F Sacchi; H R Hill; D E Van Epps; R A Daynes
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

4.  Waves of larch budmoth outbreaks in the European alps.

Authors:  Ottar N Bjørnstad; Mikko Peltonen; Andrew M Liebhold; Werner Baltensweiler
Journal:  Science       Date:  2002-11-01       Impact factor: 47.728

5.  Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia.

Authors:  L L Laichalk; K A Bucknell; G B Huffnagle; J M Wilkowski; T A Moore; R J Romanelli; T J Standiford
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons.

Authors:  J Taranger; B Trollfors; E Bergfors; N Knutsson; V Sundh; T Lagergård; L Lind-Brandberg; G Zackrisson; J White; H Cicirello; J Fusco; J B Robbins
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

7.  Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences.

Authors:  A van der Zee; F Mooi; J Van Embden; J Musser
Journal:  J Bacteriol       Date:  1997-11       Impact factor: 3.490

8.  Disease extinction and community size: modeling the persistence of measles.

Authors:  M J Keeling; B T Grenfell
Journal:  Science       Date:  1997-01-03       Impact factor: 47.728

9.  Frequency of unrecognized Bordetella pertussis infections in adults.

Authors:  J G Deville; J D Cherry; P D Christenson; E Pineda; C T Leach; T L Kuhls; S Viker
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

10.  Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation.

Authors:  B D Meade; P D Kind; C R Manclark
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

View more
  70 in total

1.  Clearance of Bordetella parapertussis from the lower respiratory tract requires humoral and cellular immunity.

Authors:  Daniel N Wolfe; Girish S Kirimanjeswara; Eric T Harvill
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis.

Authors:  Xuqing Zhang; Sara E Hester; Mary J Kennett; Alexia T Karanikas; Liron Bendor; David E Place; Eric T Harvill
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

3.  Characterizing extravascular neutrophil migration in vivo in the iris.

Authors:  Stephen R Planck; Matthias D Becker; Sergio Crespo; Dongseok Choi; Kellen Galster; Kiera L Garman; Rainer Nobiling; James T Rosenbaum
Journal:  Inflammation       Date:  2008-01-15       Impact factor: 4.092

4.  Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection.

Authors:  Karen M Scanlon; Yael Gau; Jingsong Zhu; Ciaran Skerry; Susan M Wall; Manoocher Soleimani; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

5.  Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Merete Bolstad; Synne Sandbu; Hilde Bakke; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

6.  Role of the type III secretion system in a hypervirulent lineage of Bordetella bronchiseptica.

Authors:  Anne M Buboltz; Tracy L Nicholson; Laura S Weyrich; Eric T Harvill
Journal:  Infect Immun       Date:  2009-07-13       Impact factor: 3.441

Review 7.  Toward a mechanism-based in vitro safety test for pertussis toxin.

Authors:  Stefan F C Vaessen; Martijn W P Bruysters; Rob J Vandebriel; Saertje Verkoeijen; Rogier Bos; Cyrille A M Krul; Arnoud M Akkermans
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

8.  Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.

Authors:  Karen Scanlon; Ciaran Skerry; Nicholas Carbonetti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 9.  Virulence factor secretion and translocation by Bordetella species.

Authors:  Ruchi Shrivastava; Jeff F Miller
Journal:  Curr Opin Microbiol       Date:  2009-01-29       Impact factor: 7.934

10.  O antigen protects Bordetella parapertussis from complement.

Authors:  Elizabeth M Goebel; Daniel N Wolfe; Kelly Elder; Scott Stibitz; Eric T Harvill
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.